Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes.

Next Previous
X
Search
Trial Profile

VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varespladib (Primary) ; Atorvastatin
  • Indications Acute coronary syndromes; Angina pectoris; Myocardial infarction
  • Focus Registrational; Therapeutic Use
  • Acronyms VISTA-16
  • Sponsors Anthera Pharmaceuticals

    • Most Recent Events

    • 31 Jul 2022 This trial has been completed in Spain, according to European Clinical Trials Database record.
    • 18 Nov 2013 Interim results published in JAMA: the Journal of the American Medical Association.
    • 11 Apr 2012 New source identified and integrated (Clinical Trials Registry - India: CTRI2011-05-001713)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top